Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Surprise As Amgen Passes Regeneron/Sanofi To First PCSK9 Inhibitor Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

While all eyes were on the U.S. market, Amgen clinched victory over Regeneron/Sanofi in the race to be first to approval with a PCSK9 inhibitor in another major territory, the EU.

You may also be interested in...



How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.

Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows

The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.

Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval

Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel